Table 2.

Comparison of Adverse Events of TKIs Used in the Frontline Setting for Patients with Chronic Phase CML

Standard Daily Dosage	Imatinib 400 mg	Nilotinib 600 mg or 800 mg	Dasatinib 100 mg
Nonhematologic (all grades)
Fatigue	+	+	+
Headache	+	++	+
Nausea	+++	++	+
Vomiting	+	+	+
Diarrhea	++	+	++
Rash	++	+++	++
Muscle Spasm	+++	+	+/−
Myalgia	+	+	+
Peripheral Edema	++	+	+
Periorbital Edema	++	+/−	+/−
Pleural Effusion	−	−	++
QTc > 500 msec	+/−	+/−	+/−
Laboratory Abnormalities (grade 3 or 4)
Neutropenia	++	++	+++
Anemia	+	++	+
Thrombocytopenia	+	++	+++
Hyperglycemia	−	+	−
Hypophosphatemia	++	+	+
Elevated Transaminases	+/−	+	+/−
Hyperbilirubinemia	+/−	+	+/−

Data based on frontline TKI studies in CML patients (Kantarjian et.al N Engl J Med. 2010⁴⁰; Saglio et al. N Engl J Med. 2010³³).

Key: +++ = more than 20%; ++ = 10%–20%; + =5%–10%; +/− = less than 5%; - = rare or no information. Values are approximations in some cases.